Connect Biopharma (CNTB) Competitors $0.68 -0.08 (-10.53%) Closing price 03/28/2025 03:59 PM EasternExtended Trading$0.72 +0.04 (+5.29%) As of 03/28/2025 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CNTB vs. OCGN, GNFT, CGC, ACRV, PRQR, RAPT, TARA, PBYI, NBTX, and FULCShould you be buying Connect Biopharma stock or one of its competitors? The main competitors of Connect Biopharma include Ocugen (OCGN), Genfit (GNFT), Canopy Growth (CGC), Acrivon Therapeutics (ACRV), ProQR Therapeutics (PRQR), RAPT Therapeutics (RAPT), Protara Therapeutics (TARA), Puma Biotechnology (PBYI), Nanobiotix (NBTX), and Fulcrum Therapeutics (FULC). These companies are all part of the "pharmaceutical products" industry. Connect Biopharma vs. Ocugen Genfit Canopy Growth Acrivon Therapeutics ProQR Therapeutics RAPT Therapeutics Protara Therapeutics Puma Biotechnology Nanobiotix Fulcrum Therapeutics Ocugen (NASDAQ:OCGN) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, community ranking, valuation and institutional ownership. Do insiders & institutionals believe in OCGN or CNTB? 10.3% of Ocugen shares are owned by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are owned by institutional investors. 4.3% of Ocugen shares are owned by insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has better valuation & earnings, OCGN or CNTB? Connect Biopharma has higher revenue and earnings than Ocugen. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOcugen$4.06M57.57-$63.08M-$0.19-4.21Connect Biopharma$24.12M1.56-$59.50MN/AN/A Does the MarketBeat Community believe in OCGN or CNTB? Ocugen received 95 more outperform votes than Connect Biopharma when rated by MarketBeat users. However, 72.00% of users gave Connect Biopharma an outperform vote while only 71.07% of users gave Ocugen an outperform vote. CompanyUnderperformOutperformOcugenOutperform Votes11371.07% Underperform Votes4628.93% Connect BiopharmaOutperform Votes1872.00% Underperform Votes728.00% Does the media refer more to OCGN or CNTB? In the previous week, Ocugen had 3 more articles in the media than Connect Biopharma. MarketBeat recorded 6 mentions for Ocugen and 3 mentions for Connect Biopharma. Connect Biopharma's average media sentiment score of 1.44 beat Ocugen's score of 1.27 indicating that Connect Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocugen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Connect Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, OCGN or CNTB? Ocugen has a beta of 3.88, meaning that its stock price is 288% more volatile than the S&P 500. Comparatively, Connect Biopharma has a beta of -0.47, meaning that its stock price is 147% less volatile than the S&P 500. Is OCGN or CNTB more profitable? Connect Biopharma has a net margin of 0.00% compared to Ocugen's net margin of -532.51%. Connect Biopharma's return on equity of 0.00% beat Ocugen's return on equity.Company Net Margins Return on Equity Return on Assets Ocugen-532.51% -154.75% -90.79% Connect Biopharma N/A N/A N/A Do analysts recommend OCGN or CNTB? Ocugen currently has a consensus price target of $6.33, suggesting a potential upside of 692.16%. Connect Biopharma has a consensus price target of $8.00, suggesting a potential upside of 1,076.47%. Given Connect Biopharma's higher possible upside, analysts plainly believe Connect Biopharma is more favorable than Ocugen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ocugen 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Connect Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryConnect Biopharma beats Ocugen on 10 of the 15 factors compared between the two stocks. Remove Ads Get Connect Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNTB vs. The Competition Export to ExcelMetricConnect BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$37.57M$6.90B$5.63B$7.83BDividend YieldN/A2.74%4.57%4.01%P/E RatioN/A7.1723.3318.67Price / Sales1.56218.11387.5690.67Price / CashN/A65.6738.1634.64Price / Book0.376.396.894.23Net Income-$59.50M$142.12M$3.20B$247.15M7 Day Performance-15.63%-5.06%-2.98%-2.17%1 Month Performance-24.70%-7.49%1.63%-5.68%1 Year Performance-60.92%-10.91%9.44%-0.74% Connect Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNTBConnect Biopharma3.5361 of 5 stars$0.68-10.5%$8.00+1,076.5%-60.9%$37.57M$24.12M0.00110Short Interest ↓News CoverageGap UpOCGNOcugen1.1797 of 5 stars$0.64+5.4%$6.33+893.6%-51.3%$176.55M$4.06M-3.5480Analyst RevisionPositive NewsGNFTGenfit2.106 of 5 stars$3.53-2.8%$13.00+268.3%+1.8%$176.49M$76.06M0.00120Upcoming EarningsCGCCanopy Growth2.4016 of 5 stars$1.16+4.5%$2.00+72.4%-88.6%$176.06M$276.75M-0.313,150Positive NewsACRVAcrivon Therapeutics2.2952 of 5 stars$5.61+4.7%$23.67+321.9%-68.7%$174.67MN/A-2.0858Earnings ReportAnalyst ForecastAnalyst RevisionNews CoveragePRQRProQR Therapeutics1.9725 of 5 stars$1.65flat$9.50+475.8%-38.3%$173.60M$18.91M-5.16180Analyst RevisionPositive NewsGap UpRAPTRAPT Therapeutics3.8694 of 5 stars$1.53+16.8%$5.29+245.5%-86.4%$172.93M$1.53M-0.5580TARAProtara Therapeutics2.3566 of 5 stars$4.70+2.2%$22.50+378.7%+14.2%$172.81MN/A-1.6730Short Interest ↓Gap UpPBYIPuma Biotechnology4.3241 of 5 stars$3.47-1.1%$7.00+101.7%-40.8%$172.15M$230.47M7.23200NBTXNanobiotix2.6015 of 5 stars$3.62-0.1%$12.00+231.9%-44.2%$170.43M$36.22M0.00100Short Interest ↓News CoverageFULCFulcrum Therapeutics1.713 of 5 stars$3.21+1.9%$8.63+168.7%-68.1%$170.03M$80M-10.35100News CoveragePositive News Remove Ads Related Companies and Tools Related Companies OCGN Competitors GNFT Competitors CGC Competitors ACRV Competitors PRQR Competitors RAPT Competitors TARA Competitors PBYI Competitors NBTX Competitors FULC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNTB) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Connect Biopharma Holdings Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Connect Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CNTB Stock Free CNTB Stock Alerts